Showing results (2551-2560 of 3,349) with videos related to

Sort By:
Pageof 335
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2014
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)Gerald S Falchook, Georgina V Long, Razelle Kurzrock, et al.
Ebiomedicine|August 16, 2016
Sickle Cell Trait Increases Red Blood Cell Storage Hemolysis and Post-Transfusion Clearance in MiceDavid O Osei-Hwedieh, Tamir Kanias, Claudette St Croix, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|October 8, 2016
Characteristics of cefazolin inoculum effect-positive methicillin-susceptible staphylococcus aureus infection in a multicentre bacteraemia cohortK-H Song, S-I Jung, S Lee, et al.
Pharmacogenetics and Genomics|October 19, 2006
Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group studyAlison A Motsinger, Marylyn D Ritchie, Robert W Shafer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanomaPaolo A Ascierto, David Minor, Antoni Ribas, et al.
JCI Insight|September 29, 2022
Cell-free and alkylated hemoproteins improve survival in mouse models of carbon monoxide poisoningQinzi Xu, Jason J Rose, Xiukai Chen, et al.
Vaccine|October 16, 2015
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccinesThomas L Richie, Peter F Billingsley, B Kim Lee Sim, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2014
Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trialA M Menzies, M T Ashworth, S Swann, et al.
Pageof 335